Cancer Family
Thymus Epithelial Neoplasm
CI-CAN-00000365Explore in graph →
Non-malignant39 active trials1 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000365Explore in graph →
Clinical trials
136 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03076554 | A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy | active not recruiting | Phase 2 | 56 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT06980077 | Ivonescimab for the Treatment of Thymic Cancer | recruiting | Phase 2 | 25 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07824505 | Lucitanib (AL3810) in Patients With Advanced Thymic Carcinoma After Chemotherapy | completed | Phase 2 | 74 | Haihe Biopharma Co., Ltd.INDUSTRY | 1 | Sep 17, 2026 | clinicaltrials |
| NCT06248515 | A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial Tumors | recruiting | Phase 2 | 18 | Georgetown UniversityOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT04417660 | Bintrafusp Alfa (M7824) in Subjects With Thymoma and Thymic Carcinoma | active not recruiting | Phase 2 | 9 | National Cancer Institute (NCI)NIH | 1 | Aug 28, 2026 | clinicaltrials |
| NCT05104736 | PT-112 in Subjects With Thymoma and Thymic Carcinoma | recruiting | Phase 2 | 53 | National Cancer Institute (NCI)NIH | 1 | Aug 28, 2026 | clinicaltrials |
| NCT07324629 | Sacituzumab Tirumotecan in Participants With Locally Advanced or Metastatic Thymic Carcinoma | recruiting | Phase 2 | 30 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 12, 2026 | clinicaltrials |
| NCT03463460 | Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer | active not recruiting | Phase 2 | 9 | Dwight OwenOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07750353 | A Phase II, Investigator-Initiated Exploratory Study of Sacituzumab Tirumotecan for Previously Treated Unresectable Thymic Carcinomas(XANTHOS) | not yet recruiting | Phase 2 | 35 | National Cancer Center, JapanOTHER_GOV | 1 | Aug 6, 2026 | clinicaltrials |
| NCT01025089 | Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma | active not recruiting | Phase 2 | 18 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT07691619 | Hypofractionated Radiotherapy After Complete Resection for Stage II/III Thymic Epithelial Tumors(TET-HFRT40) | recruiting | Phase 2 | 49 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT06790706 | IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers(IMMUNORARE5) | active not recruiting | Phase 2 | 27 | Hospices Civils de LyonOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT07598955 | Target-Selected CAR-NK Cells (CD30, CD5, or Mesothelin) for Relapsed/Refractory B2 Thymoma or Thymic Carcinoma(SELECT-NK-THYM) | recruiting | Phase 1 / Phase 2 | 36 | Beijing BiotechINDUSTRY | 1 | May 20, 2026 | clinicaltrials |
| NCT03134118 | Nivolumab in Patients With Type B3 Thymoma and Thymic Carcinoma (NIVOTHYM)(NIVOTHYM) | active not recruiting | Phase 2 | 55 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 6 | May 15, 2026 | clinicaltrials |
| NCT06019468 | Neoadjuvant Treatment For Locally Advanced Thymic Cancer | recruiting | Phase 2 | 25 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT07479628 | Neoadjuvant Adebrelimab Plus CRT for Locally Advanced Thymic Carcinoma | not yet recruiting | Phase 2 | 31 | Shanghai Chest HospitalOTHER | 0 | Mar 18, 2026 | clinicaltrials |
| NCT04710628 | Combination of Pembrolizumab and Lenvatinib, in Pre-treated Thymic CArcinoma paTIents(PECATI) | completed | Phase 2 | 43 | MedSIROTHER | 3 | Feb 19, 2026 | clinicaltrials |
| NCT07343453 | A Single-Arm, Phase II Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan in Second-Line and Subsequent Treatments for Advanced Thymic Epithelial Tumors | not yet recruiting | Phase 2 | 38 | Sun Yat-sen UniversityOTHER | 0 | Jan 15, 2026 | clinicaltrials |
| NCT06838910 | Tislelizumab Combined With Anlotinib as Second-line Therapy in Thymoma and Thymic Carcinoma | recruiting | Phase 2 | 20 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Dec 1, 2025 | clinicaltrials |
| NCT03694002 | Carboplatin and Paclitaxel With or Without Ramucirumab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Thymic Cancer That Cannot Be Removed by Surgery | completed | Phase 2 | 21 | SWOG Cancer Research NetworkNETWORK | 1 | Oct 30, 2025 | clinicaltrials |
| NCT06186726 | Clinical Study of Carbon Ion Radiotherapy Combined With Chemotherapy for Thymic Epithelial Tumors | recruiting | Phase 2 | 48 | Jian ChenOTHER | 1 | Jun 13, 2025 | clinicaltrials |
| NCT06311955 | Clinical Study of Postoperative Carbon Ion Radiotherapy for Thymus Tumor With Residual Tumor | recruiting | Phase 2 | 48 | Jian ChenOTHER | 1 | Jun 13, 2025 | clinicaltrials |
| NCT06311968 | The Clinical Study of Post-operative Proton Radiotherapy for Thymus Tumor | recruiting | Phase 2 | 55 | Jian ChenOTHER | 1 | Jun 13, 2025 | clinicaltrials |
| NCT06730308 | Glucocorticoids Combined With Concurrent Chemoradiotherapy for Unresectable Thymoma | recruiting | Phase 2 | 45 | Sun Yat-sen UniversityOTHER | 1 | Dec 12, 2024 | clinicaltrials |
| NCT06654830 | RATT Vs. VATT for Early-stage TETs | not yet recruiting | Phase 2 | 100 | Shanghai Zhongshan HospitalOTHER | 0 | Oct 30, 2024 | clinicaltrials |
| NCT03583086 | Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors | completed | Phase 1 / Phase 2 | 88 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Oct 8, 2024 | clinicaltrials |
| NCT01306045 | Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies | completed | Phase 2 | 647 | National Cancer Institute (NCI)NIH | 1 | Oct 1, 2024 | clinicaltrials |
| NCT01621568 | Sunitinib for Advanced Thymus Cancer Following Earlier Treatment | completed | Phase 2 | 56 | National Cancer Institute (NCI)NIH | 1 | Sep 24, 2024 | clinicaltrials |
| NCT04321330 | A Study to Investigate the Efficacy and Safety of Atezolizumab (Tecentriq) in Previously-Treated Patients With Advanced Thymic Carcinoma | completed | Phase 2 | 34 | Hoffmann-La RocheINDUSTRY | 1 | Jun 11, 2024 | clinicaltrials |
| NCT03921671 | Ramucirumab and Carbo-Paclitaxel for Untreated Thymic Carcinoma / B3 Thymoma With Carcinoma (RELEVENT)(RELEVENT) | unknown | Phase 2 | 60 | Claudia ProtoOTHER | 1 | May 29, 2024 | clinicaltrials |
| NCT04925947 | A Study of KN046 in Patients With Thymic Carcinoma Who Failed Immune Checkpoint Inhibitors | terminated | Phase 2 | 4 | Weill Medical College of Cornell UniversityOTHER | 1 | Apr 16, 2024 | clinicaltrials |
| NCT06200233 | Rivoceranib in Patients With Metastatic Thymic Epithelial Tumor | not yet recruiting | Phase 2 | 40 | Samsung Medical CenterOTHER | 1 | Apr 9, 2024 | clinicaltrials |
| NCT04469725 | KN046 (a Humanized PD-L1/CTLA4 Bispecific Single Domain Fc Fusion Protein Antibody) in Subjects With Thymic Carcinoma | terminated | Phase 2 | 95 | Jiangsu Alphamab Biopharmaceuticals Co., LtdINDUSTRY | 1 | Mar 12, 2024 | clinicaltrials |
| NCT05832827 | First-line CBDCA/PTX/LEN/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas (Artemis)(Artemis) | recruiting | Phase 2 | 35 | National Cancer Center, JapanOTHER_GOV | 1 | Oct 23, 2023 | clinicaltrials |
| NCT00010257 | Carboplatin Combined With Paclitaxel in Treating Patients With Advanced Thymoma | completed | Phase 2 | 46 | Eastern Cooperative Oncology GroupNETWORK | 1 | Jun 29, 2023 | clinicaltrials |
| NCT00003283 | Octreotide With or Without Prednisone in Treating Patients With Metastatic or Recurrent Thymoma | completed | Phase 2 | 38 | Eastern Cooperative Oncology GroupNETWORK | 2 | Jun 15, 2023 | clinicaltrials |
| NCT04667793 | Clinical Study of Neoadjuvant PD-1 Antibody (Toripalimab) Plus Chemotherapy for Locally Advanced Thymic Epithelial Tumor | unknown | Phase 2 | 15 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Apr 4, 2023 | clinicaltrials |
| NCT04276597 | Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET.(PUTNET) | withdrawn | Phase 2 | 0 | Excel Diagnostics and Nuclear Oncology CenterOTHER | 1 | Mar 10, 2023 | clinicaltrials |
| NCT03193437 | Selinexor in Patients With Advanced Thymic Epithelial Tumor Progressing After Primary Chemotherapy(SELECT) | terminated | Phase 2 | 8 | Georgetown UniversityOTHER | 1 | Feb 16, 2023 | clinicaltrials |
| NCT02049047 | Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Chemotherapy(ONC-2010-001) | completed | Phase 2 | 41 | Armando Santoro, MDOTHER | 1 | Sep 10, 2022 | clinicaltrials |
| NCT02307500 | Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy(RESOUND) | completed | Phase 2 | 82 | Istituto Clinico HumanitasOTHER | 1 | Sep 10, 2022 | clinicaltrials |
| NCT04371458 | Thymectomy With and Without Povidone-iodine Pleural Lavage in Stage IVA Thymic Malignancies | withdrawn | Phase 1 / Phase 2 | 0 | Yale UniversityOTHER | 0 | Jul 25, 2022 | clinicaltrials |
| NCT05407649 | Abscopal Effect of Radiotherapy in Combination With rhGM-CSF for Advanced Thymic Epithelial Tumours | unknown | Phase 2 | 60 | Shanghai Cancer Hospital, ChinaOTHER | 1 | Jun 7, 2022 | clinicaltrials |
| NCT02220855 | A Study of BKM120 (Buparlisib) in Relapsed or Refractory Thymomas | completed | Phase 2 | 14 | Patrick Joseph Loehrer Sr.OTHER | 1 | Apr 11, 2022 | clinicaltrials |
| NCT03663764 | Hypofractionated Chemoradiotherapy and Thymosin α1 in Unresectable or Recurrent Thymic Epithelial Tumor | unknown | Phase 2 | 57 | Sun Yat-sen UniversityOTHER | 1 | Dec 10, 2021 | clinicaltrials |
| NCT03449173 | Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines (Style Trial)(Style) | unknown | Phase 2 | 56 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Jun 9, 2021 | clinicaltrials |
| NCT03858582 | neoadjuvant_thymic Epithelial Tumor | unknown | Phase 2 | 40 | Samsung Medical CenterOTHER | 1 | Mar 22, 2021 | clinicaltrials |
| NCT04517539 | Abscopal Effect of SBRT in Combination With rhGM-CSF and INF-α 2b for Metastatic Thymic Epithelial Tumors | unknown | Phase 2 | 65 | Shanghai Cancer Hospital, ChinaOTHER | 1 | Aug 18, 2020 | clinicaltrials |
| NCT02607631 | A Study of Pembrolizumab for Patients With Thymic Epithelial Tumor | completed | Phase 2 | 33 | Samsung Medical CenterOTHER | 0 | Jul 9, 2020 | clinicaltrials |
Data updated yesterdaySource updated Sep 28, 2026source: clinicaltrials